Patients who are diagnosed with bladder cancer that has penetrated nearby muscles (“muscle-invasive bladder cancer”) undergo surgery to have the bladder removed (cystectomy). Studies have shown that patients who receive chemotherapy before this surgery (“neoadjuvant chemotherapy”) live longer than those who have the surgery alone.
Gemcitabine and carboplatin are drugs commonly used for neoadjuvant treatment of muscle-invasive bladder cancer. In this study, researchers are assessing the safety and effectiveness of adding a third drug, panitumumab, to this drug combination as neoadjuvant therapy for patients with muscle-invasive bladder cancer.
Panitumumab is approved for treating advanced colorectal cancer, but its use for bladder cancer is considered investigational. It works by binding to and blocking a protein called epidermal growth factor receptor.